China is emerging as a significant destination for medical tourism, particularly for cutting-edge CAR-T cell therapy. Patients from countries like Australia are increasingly traveling to Shanghai for treatment, citing costs that are approximately ten times lower than in the United States or the United Kingdom. Beyond affordability, the Chinese healthcare system offers faster manufacturing timelines for T-cells, which is critical for patients with rapidly progressing blood cancers. Amanda Harvey, a doctor and patient, highlights the efficiency of Chinese hospitals, while industry expert Sandeep Womne attributes China’s leadership to massive government investment, large-scale manufacturing facilities, and intense market competition. This model allows for the treatment of a high volume of patients, generating extensive data that further accelerates innovation in oncology.
Sign in to continue reading, translating and more.
Open full episode in Podwise